EU Approves Rheumatoid Arthritis Drug Of Japan’s Chugai
This article was originally published in PharmAsia News
Executive Summary
The European Union has approved a rheumatoid-arthritis drug developed by Japan's Chugai Pharmaceutical, now controlled by Roche. The drug is RoActemra (tocilizumab), whose U.S. approval as Actemra is being delayed for 18 months because the FDA wants a new animal test and additional information. Analysts estimate annual sales of at least $2 billion. Roche has the rights to market Actemra outside Japan. Roche said the drug will be sold with another drug for patients who fail to respond to other treatments. (Click here for more - a subscription may be required
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.